Continuous infusion of coagulation factors is becoming increasingly po
pular, and is mirrored by the accelerating rate of publications on thi
s topic. However, several questions remain, particularly regarding eff
icacy. For this purpose, well designed trials are required. Some guide
lines for such trials are presented here.